news

NHS England to fund bionic eye surgery

0
SHARES

Posted: 3 January 2017 | | No comments yet

Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in RP…

NHS England will provide funding for further testing of the Argus II, also known as the Bionic Eye.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Ten patients will undergo surgery to tackle Retinitis pigmentosa, an inherited disease that causes blindness. The procedures will take place at Manchester Eye Hospital and Moorfields Eye Hospital in 2017.

NHS England will fund this through its Commissioning through Evaluation (CtE) scheme, designed to gather vital evidence for treatments that show significant promise for the future. NHS England will assess how the Bionic Eye helps patients function with everyday tasks.

Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in Retinitis pigmentosa. Specialists at both hospitals initially supported early studies, which demonstrated that the Argus II restores a degree of visual function to patients who have suffered complete blindness due to the condition.

Patients using the system, developed by American company Second Sight Medical Products, are given an implant into their retina and a camera mounted on a pair of glasses sends wireless signals direct to the nerves which control sight. The signals are then ‘decoded’ by the brain as flashes of light.

Professor Paulo Stanga from Manchester Royal Eye Hospital, University of Manchester, who performed one of the surgeries, said, “I’m delighted that our pioneering research has provided the evidence to support NHS England’s decision to fund the bionic eye for the first time for patients. It surpassed all of our expectations when we realised that one of the RP patients in Manchester using the bionic eye could identify large letters for the first time in his adult life.”

Procedures will take place during 2017 and patients will then be monitored for a period of one year, during which they will be assessed on how the implants improve their everyday lives.

Related topics

Related organisations

Related diseases & conditions

Share via
Share via